Your browser doesn't support javascript.
loading
The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects.
Vicenti, Ilaria; Gatti, Francesca; Scaggiante, Renzo; Boccuto, Adele; Zago, Daniela; Basso, Monica; Dragoni, Filippo; Parisi, Saverio Giuseppe; Zazzi, Maurizio.
Afiliação
  • Vicenti I; Department of Medical Biotechnologies, University of Siena, Siena, Italy.
  • Gatti F; Department of Molecular Medicine, University of Padova, Via Gabelli 63, 35121, Padova, Italy.
  • Scaggiante R; Belluno Hospital, Belluno, Italy.
  • Boccuto A; Department of Medical Biotechnologies, University of Siena, Siena, Italy.
  • Zago D; Department of Molecular Medicine, University of Padova, Via Gabelli 63, 35121, Padova, Italy.
  • Basso M; Department of Molecular Medicine, University of Padova, Via Gabelli 63, 35121, Padova, Italy.
  • Dragoni F; Department of Medical Biotechnologies, University of Siena, Siena, Italy.
  • Parisi SG; Department of Molecular Medicine, University of Padova, Via Gabelli 63, 35121, Padova, Italy. saverio.parisi@unipd.it.
  • Zazzi M; Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Infection ; 50(2): 541-543, 2022 04.
Article em En | MEDLINE | ID: mdl-34342854
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Vacina BNT162 Limite: Humans Idioma: En Revista: Infection Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Vacina BNT162 Limite: Humans Idioma: En Revista: Infection Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália